ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

HYPR Hyperfine Inc

1.02
0.1326 (14.94%)
Last Updated: 16:43:45
Delayed by 15 minutes
Share Name Share Symbol Market Type
Hyperfine Inc NASDAQ:HYPR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.1326 14.94% 1.02 1.00 1.02 1.0299 0.8999 0.90 275,310 16:43:45

Hyperfine, Inc. to Announce Third Quarter Financial Results on November 9, 2023

19/10/2023 9:05pm

Business Wire


Hyperfine (NASDAQ:HYPR)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Hyperfine Charts.

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2023 on Thursday, November 9, 2023. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.’s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call.

About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that has redefined brain imaging with the Swoop® system—the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020 as a portable magnetic resonance brain imaging device for producing images that display the internal structure of the head where a full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system has been approved for brain imaging in several countries, including Canada and Australia, has UKCA certification in the United Kingdom, CE certification in the European Union, and is also available in New Zealand.

The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. Traditionally, access to costly, stationary, conventional MRI technology can be inconvenient or not available when needed most. With the portable, ultra-low-field Swoop® system, Hyperfine, Inc. is redefining the neuroimaging workflow by bringing brain imaging to the patient’s bedside. For more information, visit hyperfine.io.

Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

Investor Contact Marissa Bych Gilmartin Group LLC marissa@gilmartinir.com

1 Year Hyperfine Chart

1 Year Hyperfine Chart

1 Month Hyperfine Chart

1 Month Hyperfine Chart

Your Recent History

Delayed Upgrade Clock